Total
0
Shares
ImpediMed (ASX:IPD) - CEO, Rick Carreon
CEO, Rick Carreon
Source: Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) has completed 200,000 patient tests using the SOZO device since its launch in October 2017
  • SOZO is a non-invasive, bioimpedance spectroscopy (BIS) device that delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds
  • The company says it expects testing rates to continue to accelerate as it commercialises its heart and renal failure indications
  • ImpediMed is up 9.09 per cent, trading at 12 cents

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.

SOZO is a non-invasive, bioimpedance spectroscopy (BIS) device that delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO can capture an array of data over a wide spectrum of frequencies from three kilohertz to 1000 kilohertz to maximise patient health.

Over 200,000 patient tests have been conducted since its commercial launch in October 2017. More than 28,000 patient tests were conducted in Q2 FY21 alone.

It took the company 32 months to achieve the milestone of the first 100,000 patient tests. However, it powered through after its initial launch, testing the following 100,000 patients in just 13 months.

The company says it expects testing rates to continue to accelerate as they commercialise its heart and renal failure indications.

“This is a significant milestone for our company, but more importantly for the patients whose lives have been dramatically impacted by the reduction in lymphoedema rates from SOZO testing. For the company, we are building a large dataset which will be very valuable in providing new insights into the course and care of a large number of chronic disease states,” said Managing Director and CEO of ImpediMed, Richard Carreon.

ImpediMed is up 9.09 per cent, trading at 12 cents at 3:15 pm AEDT.

IPD by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.